SRC - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
EMD	emerin	Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Depolymerisation of the Nuclear Lamina Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane		Emery-Dreifuss muscular dystrophy
FANCC	FA complementation group C	Fanconi Anemia Pathway TP53 Regulates Transcription of DNA Repair Genes		Fanconi anemia
FASLG	Fas ligand	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited Interleukin-4 and Interleukin-13 signaling Dimerization of procaspase-8 FasL/ CD95L signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models FOXO-mediated transcription of cell death genes TNFs bind their physiological receptors		Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
FLT3	fms related receptor tyrosine kinase 3	PI3K Cascade PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling FLT3 Signaling FLT3 Signaling STAT5 Activation FLT3 mutants bind TKIs STAT5 activation downstream of FLT3 ITD mutants KW2449-resistant FLT3 mutants semaxanib-resistant FLT3 mutants crenolanib-resistant FLT3 mutants gilteritinib-resistant FLT3 mutants lestaurtinib-resistant FLT3 mutants midostaurin-resistant FLT3 mutants pexidartinib-resistant FLT3 mutants ponatinib-resistant FLT3 mutants quizartinib-resistant FLT3 mutants sorafenib-resistant FLT3 mutants sunitinib-resistant FLT3 mutants tandutinib-resistant FLT3 mutants linifanib-resistant FLT3 mutants tamatinib-resistant FLT3 mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Negative regulation of FLT3 FLT3 signaling through SRC family kinases FLT3 signaling through SRC family kinases FLT3 signaling by CBL mutants	Sorafenib Sunitinib XL999 Tandutinib ABT-869 Lestaurtinib Midostaurin Ponatinib Nintedanib Fostamatinib Gilteritinib Brigatinib Fedratinib Amuvatinib Quizartinib Pexidartinib Pralsetinib	Acute myeloid leukemia (AML)
FOXO1	forkhead box O1	AKT phosphorylates targets in the nucleus Regulation of gene expression in beta cells AKT-mediated inactivation of FOXO1A Constitutive Signaling by AKT1 E17K in Cancer MAPK6/MAPK4 signaling Interleukin-4 and Interleukin-13 signaling Regulation of localization of FOXO transcription factors FOXO-mediated transcription of cell death genes FOXO-mediated transcription of cell death genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Regulation of FOXO transcriptional activity by acetylation Regulation of FOXO transcriptional activity by acetylation FOXO-mediated transcription of cell cycle genes FOXO-mediated transcription of cell cycle genes		Alveolar rhabdomyosarcoma
GFAP	glial fibrillary acidic protein	Nuclear signaling by ERBB4 Chaperone Mediated Autophagy		Alexander disease
GJB1	gap junction protein beta 1	Oligomerization of connexins into connexons Oligomerization of connexins into connexons Transport of connexins along the secretory pathway Gap junction assembly		Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
HNF1A	HNF1 homeobox A	Regulation of gene expression in beta cells	D-norleucine	Maturity onset diabetes of the young (MODY)
KCNA5	potassium voltage-gated channel subfamily A member 5	Voltage gated Potassium channels	Enflurane Promethazine Miconazole Vernakalant Dalfampridine Isavuconazole	Atrial fibrillation
MAP2K1	mitogen-activated protein kinase kinase 1	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide PD-0325901 N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
MT-ND2	NADH dehydrogenase subunit 2	Respiratory electron transport Complex I biogenesis	NADH	Leber optic atrophy; Leber hereditary optic atrophy (LHON)
MYLK	myosin light chain kinase	Smooth Muscle Contraction RHO GTPases activate PAKs RHO GTPases activate PAKs	Fostamatinib	Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
NOS2	nitric oxide synthase 2	ROS and RNS production in phagocytes Nitric oxide stimulates guanylate cyclase Interleukin-4 and Interleukin-13 signaling Peroxisomal protein import Peroxisomal protein import Inhibition of nitric oxide production	Arginine Citrulline Minocycline Miconazole Dexamethasone N,N-dimethylarginine 4R-Fluoro-N6-ethanimidoyl-L-lysine 3-Bromo-7-Nitroindazole N-[3-(aminomethyl)benzyl]acetamidine 7-Nitroindazole S-Ethylisothiourea Thiocoumarin N-omega-propyl-L-arginine 6-Nitroindazole N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine Imidazole N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide Thiocitrulline L-erythro-7,8-dihydrobiopterin 5-Nitroindazole KD7040 Fenoxaprop-ethyl Pimagedine 5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE 4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile (2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine (3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine 4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINE (3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINE 4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDE ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE 1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE 4-(1H-IMIDAZOL-1-YL)PHENOL 1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE Triflusal Levamlodipine Dipyrithione Dexamethasone acetate	Esophageal cancer
NPHS1	NPHS1 adhesion molecule, nephrin	Nephrin family interactions Nephrin family interactions		Nephrotic syndrome and focal segmental glomerulosclerosis
NR3C1	nuclear receptor subfamily 3 group C member 1	HSP90 chaperone cycle for steroid hormone receptors (SHR) Circadian Clock SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS	Flunisolide Diflorasone Alclometasone Medrysone Amcinonide Fluorometholone Megestrol acetate Levonorgestrel Beclomethasone dipropionate Progesterone Spironolactone Betamethasone Desoximetasone Fluticasone propionate Fluocinolone acetonide Ulobetasol Triamcinolone Prednisone Flumethasone Fludrocortisone Norethisterone Hydrocortisone Mometasone Hydrocortamate Mifepristone Clocortolone Flurandrenolide Prednisolone Loteprednol etabonate Rimexolone Methylprednisolone Clobetasol propionate Fluocinonide Prednicarbate Fluoxymesterone Budesonide Dexamethasone Desonide Cortisone acetate Paramethasone Drospirenone Ciclesonide Hexane-1,6-Diol Aldosterone ORG-34517 Difluprednate Ulipristal Fluticasone furoate Tixocortol Difluocortolone Gestrinone Deflazacort Onapristone Cortivazol Clobetasone Fluticasone Mometasone furoate Hydrocortisone aceponate Hydrocortisone acetate Hydrocortisone butyrate Hydrocortisone cypionate Hydrocortisone phosphate Hydrocortisone probutate Hydrocortisone valerate Segesterone acetate Prednisolone phosphate Dexamethasone acetate Betamethasone phosphate Prednisolone acetate	46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
PDE6G	phosphodiesterase 6G	Activation of the phototransduction cascade Activation of the phototransduction cascade Inactivation, recovery and regulation of the phototransduction cascade Ca2+ pathway Ca2+ pathway	Sildenafil Vardenafil 3-isobutyl-1-methyl-7H-xanthine	Retinitis pigmentosa (RP)
PDGFRB	platelet derived growth factor receptor beta	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Becaplermin Sorafenib Imatinib Dasatinib Sunitinib XL999 XL820 Pazopanib Midostaurin Regorafenib Nintedanib Polaprezinc Trapidil Foreskin fibroblast (neonatal) Fostamatinib Erdafitinib Pexidartinib Ripretinib Pralsetinib	Glioma
PIP5K1C	phosphatidylinositol-4-phosphate 5-kinase type 1 gamma	Synthesis of PIPs at the plasma membrane SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Clathrin-mediated endocytosis		Lethal congenital contractural syndrome (LCCS)
PKD1	polycystin 1, transient receptor potential channel interacting	VxPx cargo-targeting to cilium VxPx cargo-targeting to cilium		Polycystic kidney disease
PTPN2	protein tyrosine phosphatase non-receptor type 2	Negative regulation of MET activity Interleukin-37 signaling		Type I diabetes mellitus

Search Results for: SRC